Although CRISPR gene editing dominates the discussion of genetic medicines, there are actually over one dozen differentiated tools. From gene therapy to antisense, RNAi to CRISPRi, CRISPR base editing to next-generation oligo-conjugates, each provides value in specific applications. No tool can do it all. Therefore, a technology-agnostic approach to genetic medicines is likely to drive the best returns for individual investors in the long run.

7investing Lead Advisor Maxx Chatsko’s recommendation for April 2021 has embarked on a methodical commercial strategy that significantly de-risks clinical development and provides a solid financial foundation for developing its next-generation technology platform.

Transcript

A drug developer that’s well-positioned to deliver on the promises of genetic medicines.

Hey everyone, I’m 7investing Lead Advisor Maxx Chatsko. Here at 7investing we empower you to invest in your future by giving you our seven best stock market opportunities each and every month, each backed by the domain competence of one of our lead advisors.

My recommendation for April 2021 is a very high risk investment, but primarily due to development risks, not valuation risks, which is important in the current market. In fact, I think this might be one of the most undervalued drug developers on the stock market.

Investors have heard all about CRISPR gene editing and there’s a lot of excitement for the approach. However, it’s interesting to me that scientists tend to have many more reservations. Many wonder if we rushed the tool into clinical trials without fully understanding the risks. I tend to agree with that perspective. This actually highlights an important reality for investors: There are over one dozen genetic medicine tools. Each adds value in specific applications, and no tool can do it all.

My recommendation is developing a next-generation technology platform that addresses some of the core obstacles encountered by all genetic medicines. The pipeline is buzzing with activity, investors can expect two to three clinical assets to be added to the pipeline each year for the foreseeable future. The approach is known to be safe and effective, while assets tend to have high rates of success if the proper genetic targets are selected. In fact, its first drug candidate could be approved and readying for this launch by this time next year.

If you want to know more about this company and the technology it’s developing, please go to 7investing.com to read my full research report. We are 7investing, and we’re here to help empower you to invest in your future.